2022-11-092022-11-092021-01-12Rey, E., Ampuero Herrojo, J., Molina-Jiménez, F., García-García, Y., Muñoz Hernández, R., Romero Gómez, M.,...,González-Rodríguez, A. (2021). Sofosbuvir improves HCV-induced insulin resistance by blocking IRS1 degradation. Clinical and translational medicine, 11 (1), e275. https://doi.org/10.1002/ctm2.275.2001-1326https://hdl.handle.net/11441/139181In the present study, we have demonstrated that sofos buvir (SOF) treatment improves systemic insulin resis tance in hepatitis C virus (HCV)-patients, and, for the first time, revealed which molecular mechanisms are involved in SOF effects on the impaired insulin response induced by HCV in hepatocytes.application/pdf5 p.engAttribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/ALTApoBGlycated hemoglobininfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccess10.1002/ctm2.275